Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02035930

Enrollment

110

Registered

2014-01-14

Start date

2010-11-30

Completion date

2012-11-30

Last updated

2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormal Menstrual Cycle

Keywords

Bispectral Index Monitor, Menstrual Cycle, Dexmedetomidine

Brief summary

The study was done to evaluate the effects of the follicular and luteal phases of the menstrual cycle on sedation level at loss of consciousness and bispectral index reach to 50 during propofol anesthesia, in patients with and without preoperative intravenous dexmedetomidine .

Interventions

DRUGdexmedetomidine

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

24 Years to 40 Years

Healthy volunteers

Inclusion criteria

* a regular menstrual cycle * elective gynecologic surgery

Exclusion criteria

* pregnancy * breastfeeding * obesity * known hypersensitivity to drugs used in the study protocol; * use of psychotropic drugs and steroids within 72 hours before the surgery * central nervous system injury * renal impairment * alcoholism and opioid addiction.

Design outcomes

Primary

Measure	Time frame
bispectral index at loss of eyelash reflex	up to 2 years

Secondary

Measure	Time frame
propofol requirements from propofol administered to loss of eyelash reflex and bispectral index reduced to 50	up to 2 years

Other

Measure	Time frame
duration from propofol administered to loss of eyelash reflex and bispectral index reduced to 50	up to 2 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026